Ongoing Trials
Parasol Dry AMD/Geographic Atrophy (81201887MDG2001) [Enrollment Closed, Trial Ongoing]
Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial To Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Gather2 ISEE2008 – Iveric Bio [Enrollment Closed, Trial Ongoing]
A Phase 3, multicenter, randomized, double-masked shamcontrolled clinical trial to assess the safety and efficacy of intravitreal administration of Zimura (complement C5 inhibitor) in patients with Geographic Atrophy secondary to Age-Related Macular Degeneration
Shore – OPT-302-1004 – OPTHEA [Enrollment Closed, Trial Ongoing]
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
EYE103-101 DME & Wet AMD [Enrollment Closed, Trial Ongoing]
A 2-part study consisting of an open-label multiple ascending dose (MAD) safety study, and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal (IVT) EYE103 in a mixed population of participants with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD)
Dream Diabetic Retinopathy (OTT166-201) [Enrollment Closed, Trial Ongoing]
A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
Pavilion GR41675 – Genentech – Roche [Enrollment Closed, Trial Ongoing]
A Phase III, Multicenter, Randomized study of the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranizumab in patients with Diabetic Retinopathy
Insite 2022-01 – McMaster University [Enrollment Closed, Trial Ongoing]
Treat & Extend versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
EYE103-101 DME & Wet AMD [Enrollment Closed, Trial Ongoing]
A 2-part study consisting of an open-label multiple ascending dose (MAD) safety study, and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal (IVT) EYE103 in a mixed population of participants with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD)
Protocol GR43828 (DME Study) [Enrollment Closed, Trial Ongoing]
A Phase I, Multicenter, Open-label study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of RO7446603 alone and co-administered with aflibercept in patients with Diabetic Macular Edema.
Elevatum- Genentech Roche [Enrollment Closed, Trial Ongoing]
A Phase IIIB/IV, Multicenter, Open-label, Single-arm study to investigate Faricimab (ro6867461) treatment response in treatment-naïve, underrepresented patients with diabetic macular edema.
Pagoda GR40550 – Genentech Roche [Enrollment Closed, Trial Ongoing]
A Phase III, Multicenter, Randomized, visual assessor masked, active comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with Diabetic Macular Edema.
For study inquiries please contact:
Diana A. CCRC, COT
Senior Clinical Research Coordinator
[email protected]
713-357-4976